N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Interview: Capital Metals – Advancing the Taprobane Minerals Project in Sri Lanka
Zak Mir talks to Greg Martyr, Executive Chairman, Capital Metals, in the wake of -
Interview with Jim Mellon: Insights on the 2025 Market Landscape and Investment Strategies
In a recent conversation with renowned investor Jim Mellon, Zak Mir delved deep -
Sam Garrett Chief Executive Officer of Great Southern Copper talking with Andrew Scott
Great Southern Copper plc (LSE: GSCU) continues to make exciting strides at its -
Zak Mir Talks to Howard White, Non-Executive Chairman of Hydrogen Utopia Intl
Zak Mir talks to Howard White, Chairman of Hydrogen Utopia, a company specialisi